Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.62 |
| ▸ | BACE1 | P56817 | 7/20 | 0.62 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.52 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13039315 | 0.80 | ACHE (0.56) | ACHEBACE1HRH3CXCR4 | |
| SCHEMBL4108213 | 0.80 | NSD2 (0.59) | ACHEBACE1EZH2MEN1POLB | |
| SCHEMBL5432812 | 0.77 | ACHE (0.69) | ACHEBACE1HRH3CXCR4 | |
| SCHEMBL13039350 | 0.77 | CXCR4 (0.57) | ACHEBACE1HRH3CXCR4 | |
| SCHEMBL18657578 | 0.76 | ACHE (0.65) | ACHEBACE1HRH3CXCR4 | |
| SCHEMBL2341635 | 0.75 | ACHE (0.64) | ACHEBACE1POLBHRH3CXCR4 | |
| SCHEMBL8487979 | 0.75 | ACHE (0.69) | ACHEBACE1EZH2EHMT2MEN1 | |
| SCHEMBL3472523 | 0.75 | ACHE (0.58) | ACHEBACE1MEN1KMT2AHRH3 | |
| SCHEMBL4516500 | 0.75 | ACHE (0.55) | ACHEBACE1HRH3CXCR4 | |
| SCHEMBL16538495 | 0.74 | ACHE (0.48) | ACHEBACE1HRH3CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221581-A1 | Methods of treating pain | CDK5, CAMKK2, CDK3 | ACHE 114/4885BACE1 4371/4885EZH2 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.